Vimedimex Pharma (VMD) Leaders Resign Ahead of 2026 AGM; HoSE Flags Late Filing
This Aveluro analysis covers VMD on HOSE in the Health Care sector. The classified event type is leadership change, with negative sentiment and a deterministic market-impact score of 5.0/10. Aveluro classifies this story as a negative catalyst and risk signal for the affected stock. Source coverage came from CafeF - Thị trường chứng khoán, classified as a primary/top-tier source.
Key Facts
Caveat: Not investment advice. · How Aveluro computed this: Aveluro combines extracted event facts, source credibility, ticker context, and market data. Scores are deterministic research signals, not recommendations.
Follow this event and trade Vietnam stocks
Use the broker guide to compare Vietnam market access before acting on this news.
Aveluro may earn a commission from broker partners. Market data and broker availability can change; confirm access before opening an account.
Overview
Vimedimex Pharmaceutical (VMD) has received resignation letters from multiple key leaders just before its 2026 Annual General Meeting (AGM), including a board member and three supervisory board members. Additionally, HoSE has reminded the company for late submission of its Q1/2026 financial reports, highlighting governance and compliance issues.
Key Facts
- Resignations include Mr. Le Tien Dung, a member of the Board of Directors (term 2022-2027).
- Three supervisory board members also resigned: Mr. Doan Duc Giang (Head), Mr. Nguyen Thanh Thanh Binh, and Mr. Truong Duy Phong.
- All resignations cite personal reasons.
- The 2026 AGM is scheduled for June 12, 2026, at 8:30 AM at Hanoi Daewoo Hotel.
- Record date for shareholder attendance is May 15, 2026.
- HoSE issued a reminder on May 6, 2026, for VMD’s late submission of Q1/2026 financial statements (both separate and consolidated) in Vietnamese and English.
- VMD shares closed at VND 14,600 on June 11, 2026, with low volume of 500 shares.
What Happened
According to a filing with HoSE, Vimedimex Pharmaceutical (VMD) received resignation letters from Mr. Le Tien Dung, a member of the Board of Directors, and three supervisory board members: Mr. Doan Duc Giang (Head), Mr. Nguyen Thanh Thanh Binh, and Mr. Truong Duy Phong. All cited personal reasons for stepping down. The resignations come just before the company’s 2026 Annual General Meeting, scheduled for June 12, 2026, at the Hanoi Daewoo Hotel.
Separately, HoSE issued a reminder on May 6, 2026, noting that VMD had failed to publish its Q1/2026 financial statements (both separate and consolidated) in Vietnamese and English by the required deadline. The exchange urged the company to comply with reporting obligations to protect shareholder interests.
Market Context
VMD shares trade on HOSE and closed at VND 14,600 on June 11, 2026, unchanged from the previous session, with extremely low volume of only 500 shares. The stock has likely been under pressure due to governance concerns and delayed financial reporting. The pharmaceutical sector in Vietnam has seen mixed performance, but VMD’s specific issues may weigh on investor sentiment.
Strategic Significance
The simultaneous resignation of multiple key leaders, including the head of the supervisory board, signals potential internal governance challenges at Vimedimex. The late filing of Q1/2026 financial reports adds to compliance risks. For long-term investors, the ability of the company to stabilize its leadership and restore timely reporting will be critical. The upcoming AGM may provide clarity on succession plans and strategic direction.
What to Watch
- Outcome of the 2026 AGM on June 12, including election of new board and supervisory board members.
- Release of Q1/2026 financial statements and any subsequent HoSE actions (e.g., warning or suspension).
- Any additional resignations or appointments in the coming weeks.
- Q2/2026 earnings report and compliance with filing deadlines.
- Share price and volume trends post-AGM as a gauge of investor confidence.